INCY Stock Price - Incyte Corp. Stock Quote (U.S.: Nasdaq) - MarketWatch

Open $65.99
Day Range 63.81 - 69.49
52 Week Range 63.81 - 142.45
Market Cap $17.59B
Shares Outstanding 211.66M
Public Float 210.37M
Beta 1.53
Rev. per Employee $1.27M
P/E Ratio n/a
EPS $-1.56
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 8.05M 03/15/18
% of Float Shorted 3.83%
Average Volume 1.68M

5 Day	-18.32%
1 Month	-27.77%
3 Month	-31.84%
YTD	-28.14%
1 Year	-51.42%

MarketWatch
Other Dow Jones

Stocks resume selloff as trade rhetoric intensifies

Apr. 6, 2018 at 12:50 p.m. ET
by Barbara Kollmeyer

Incyte stock price target cut to $70 from $94 at Evercore ISI

Apr. 6, 2018 at 9:45 a.m. ET
by Tomi Kilgore

NewLink Genetics shares plummet 39% after Merck, Incyte trial failure

NewLink Genetics Corp. shares plummeted 39.2% in premarket trade Friday after Merck and Incyte Corp. said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. NewLink has focused its research and development on IDO as a target for its cancer drugs, and its two lead therapies -- indoximod and NLG802 -- target the IDO pathway. The phase 3 trial tested Incyte's epacadostat, which is an IDO inhibitor, in combination with Merck's Keytruda, and was seen as an important trial for the entire IDO class of drugs. However, the combination did not improve progression-free survival for patients as compared with Keytruda alone, Merck and Incyte said on Friday, and the companies are stopping the trial. Drug companies have made big investments in these types of combination treatments, betting that pairing them will boost effectiveness, though Friday's trial results may undermine the theory. Bristol-Myers Squibb, another company that has invested in the IDO space, had shares decline 0.6% premarket. NewLink shares have dropped 18.7% over the last three months, compared with a 2.9% drop in the S&P 500 .

Apr. 6, 2018 at 9:14 a.m. ET
by Emma Court

Incyte's stock on track to open at 2-year low

Apr. 6, 2018 at 8:15 a.m. ET
by Tomi Kilgore

Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Shares of Incyte Corp. plunged 19% in premarket trade Friday, and Merck & Co. Inc.'s stock dropped 1.9%, after the companies said an external data monitoring committee (eDMC) determined that results from a phase 3 study evaluating Incyte's epacadostat with Merck's Keytruda in patients with metastatic melanoma did not meet the primary endpoint of improving progression-free survival. Incyte's stock had been halted until 8 a.m. ET for news. The companies said the second primary endpoint of overall survival was also not expected to reach statistical significance. The companies said they decided to stop the study based on the eDMC's recommendation. "While we are disappointed that this study did not confirm the efficacy of epacadostat in combination with KEYTRUDA in patients with unresectable or metastatic melanoma, data from ECHO-301/KEYNOTE-252, including analyses of an extensive biomarker panel, will contribute to our understanding of the role of IDO1 inhibition in combination with PD-1 antagonists, and may inform our broader epacadostat clinical development program," said Incyte's Chief Medical Officer Steven Stein. Incyte's stock had shed 16.8% over the past three months through Thursday, while Merck shares had lost 4.3% and the Dow Jones Industrial Average had slipped 3.1%.

Apr. 6, 2018 at 8:04 a.m. ET
by Tomi Kilgore

Incyte shares fall 19% after resuming trade following a halt

Apr. 6, 2018 at 8:01 a.m. ET
by Ciara Linnane

Merck shares slide 1.5% premarket after news of failed drug trial

Apr. 6, 2018 at 7:36 a.m. ET
by Ciara Linnane

Incyte, Merck don't expect phase 3 study of melanoma treatment to meet 2nd endpoint

Apr. 6, 2018 at 7:34 a.m. ET
by Tomi Kilgore

Incyte, Merck said an external DMC determined study of melanoma treatment missed endpoint

Apr. 6, 2018 at 7:33 a.m. ET
by Tomi Kilgore

Incyte stock halted premarket for news pending

Apr. 6, 2018 at 7:26 a.m. ET
by Ciara Linnane

As stocks recover, Goldman sees ‘lowered bar’ for volatility’s return

Mar. 14, 2018 at 4:22 p.m. ET
by Ryan Vlastelica

In the bull market’s ninth year, ‘winning’ stocks hide lingering pain

Mar. 10, 2018 at 4:50 p.m. ET
by Philip van Doorn

5 biotech buyout candidates you should look at right now

Jan. 28, 2018 at 1:10 p.m. ET
by Jeff Reeves

Why 2018 is a make-or-break year for pharma

Jan. 4, 2018 at 8:44 a.m. ET
by Emma Court

Biggest Nasdaq winners and losers in 2017: Chip makers, videogame publishers lead tech

Jan. 3, 2018 at 6:59 a.m. ET
by Emily Bary

S&P 500, Nasdaq end at records in first trading day of 2018; chipmakers boost tech shares

Jan. 2, 2018 at 4:29 p.m. ET
by Ryan Vlastelica

Incyte upgraded to outperform vs. sector perform at RBC

Jan. 2, 2018 at 7:54 a.m. ET
by Ciara Linnane

Analysts expect these large-cap U.S. stocks to rise at least 25% in 2018

Dec. 21, 2017 at 3:15 p.m. ET
by Philip van Doorn

Opinion

Six promising stocks to buy for the biotech rebound ahead

Nov. 21, 2017 at 8:30 a.m. ET
by Michael Brush

Best and worst earnings surprises for the S&P 500 this quarter — newly updated

Nov. 13, 2017 at 10:47 a.m. ET
by Philip van Doorn

Incyte Shares Fall After Cancer Drug Fails in Trial With Merck’s Keytruda

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies.

Apr. 6, 2018 at 12:41 p.m. ET
on The Wall Street Journal

Biotech Gets a Reality Check

The drug industry has poured billions of dollars into novel drugs that fight cancer, generating significant value for biotech investors. It is a problem, then, when potential blockbuster drugs miss the mark.

Apr. 6, 2018 at 12:01 p.m. ET
on The Wall Street Journal

Stocks to Watch: Incyte, JPMorgan, Boeing, WageWorks

Companies with shares expected to trade actively in Friday's session include Incyte, JPMorgan, Boeing and WageWorks.

Apr. 6, 2018 at 9:30 a.m. ET
on The Wall Street Journal

Celgene to Buy Impact Biomedicines

Celgene agreed to buy blood-disease biotechnology company Impact Biomedicines for as much as $7 billion.

Jan. 7, 2018 at 10:43 p.m. ET
on The Wall Street Journal

Tax Reform’s Winners and Losers

Sep. 30, 2017 at 2:50 a.m. ET
on Barron's

U.S. Stocks Slide as Oil Slump Hits Energy Sector

Jun. 20, 2017 at 5:06 p.m. ET
on The Wall Street Journal

Eli Lilly Working to Cut Costs

Apr. 25, 2017 at 7:58 a.m. ET
on The Wall Street Journal

Stocks to Watch: MoneyGram, Eli Lilly, Incyte

Apr. 17, 2017 at 9:24 a.m. ET
on The Wall Street Journal

FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug

Apr. 14, 2017 at 12:20 p.m. ET
on The Wall Street Journal

Surprise FDA Rejection Will Sting This Biotech

Apr. 14, 2017 at 12:02 p.m. ET
on The Wall Street Journal

Incyte: Why This Biotech Beauty Can Stay Hot

Apr. 12, 2017 at 6:59 p.m. ET
on Barron's

Your Cancer Drugs May Soon Be Discovered in China

Apr. 11, 2017 at 12:09 a.m. ET
on The Wall Street Journal

Tech Stocks That Sit in the Sweet Spot

Mar. 28, 2017 at 1:18 p.m. ET
on Barron's

Race Tightens for Next Wave of Cancer Drugs

Mar. 6, 2017 at 5:30 a.m. ET
on The Wall Street Journal

Biotech Executives Sign Letter Against Immigration Order

Feb. 7, 2017 at 4:55 p.m. ET
on The Wall Street Journal

More Volatility Ahead for Biotechnology Sector

Feb. 1, 2017 at 3:42 p.m. ET
on The Wall Street Journal

Drug Pricing May Linger Over Biotech in 2017

Jan. 13, 2017 at 12:05 p.m. ET
on Barron's

Smaller Biotech Buyout Targets After Medivation

Aug. 25, 2016 at 6:55 a.m. ET
on Barron's

Incyte, a Biotech Acquisition Target

Jul. 15, 2016 at 7:59 a.m. ET
on Barron's

Biotech Labs Birth New Drugs—and New Fortunes

Jun. 24, 2016 at 3:54 p.m. ET
on The Wall Street Journal

Other News
Press Releases

Incyte Shares Fall After Cancer Drug Fails in Trial With Merck’s Keytruda

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies.

Apr. 6, 2018 at 12:41 p.m. ET
on The Wall Street Journal

Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure

Apr. 6, 2018 at 12:19 p.m. ET
on InvestorPlace.com

Incyte, Merck Fall on Failed Late-Stage Study

Apr. 6, 2018 at 12:05 p.m. ET
on GuruFocus.com

Biotech Gets a Reality Check

Apr. 6, 2018 at 12:01 p.m. ET
on The Wall Street Journal

What Has Tanked Incyte and NewLink Genetics

Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.

Apr. 6, 2018 at 9:39 a.m. ET
on 247WallSt.com

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Apr. 6, 2018 at 7:50 a.m. ET
on benzinga.com

Incyte's epacadostat flunks late-stage melanoma study

Apr. 6, 2018 at 7:43 a.m. ET
on Seeking Alpha

Another April Biotech Catalyst To Watch

Apr. 4, 2018 at 8:15 a.m. ET
on Seeking Alpha

Analysts’ Recommendations for United Therapeutics in March 2018

On March 29, United Therapeutics had a consensus 12-month target price of $126.17, which represented an ~14.2% return on investment over the next 12 months.

Apr. 2, 2018 at 5:53 p.m. ET
on MarketRealist.com

How Did United Therapeutics Perform in 4Q17 and Fiscal 2017?

In 4Q17, United Therapeutics (UTHR) generated revenues of $464.7 million, up from revenues of $409.0 million in 4Q16.

Apr. 2, 2018 at 5:53 p.m. ET
on MarketRealist.com

US Markets in Red Monday

Apr. 2, 2018 at 12:32 p.m. ET
on GuruFocus.com

Concert Therapeutics Will See A Second Wind In Coming Months

Apr. 2, 2018 at 10:05 a.m. ET
on Seeking Alpha

Are Short-Sellers Right About Geron Corporation?

Apr. 2, 2018 at 6:33 a.m. ET
on Motley Fool

How Safe Is AbbVie, Inc.'s Dividend Now?

Apr. 1, 2018 at 10:31 a.m. ET
on Motley Fool

Cancer Vaccine With 97% Complete Response Rate In Mice Starts Human Trials

Apr. 1, 2018 at 6:20 a.m. ET
on Seeking Alpha

Venture Capital Deals Of The Week: Small Molecules And Software

Mar. 31, 2018 at 10:18 a.m. ET
on Seeking Alpha

10 Deceptively Bad Stocks to Sell Before You’re Pranked

Mar. 30, 2018 at 2:12 p.m. ET
on InvestorPlace.com

These 3 Biotech Stocks Are Soaring, but Are They Buys Now?

Mar. 29, 2018 at 8:48 a.m. ET
on Motley Fool

Incyte Could Have a Problem (or 2!) on Its Hands

Mar. 29, 2018 at 8:45 a.m. ET
on Motley Fool

Ionis Pharmaceuticals’ Valuation as of March 27, 2018

Wall Street analysts estimate that Ionis Pharmaceuticals (IONS) stock might increase 25.1% over the next 12 months.

Mar. 28, 2018 at 2:49 p.m. ET
on MarketRealist.com

Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Apr. 6, 2018 at 7:30 a.m. ET
on BusinessWire - BZX

Free Post Earnings Research Report: Incyte's Quarterly Sales 36% Surged

Mar. 27, 2018 at 7:01 a.m. ET
on ACCESSWIRE

Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018

Mar. 15, 2018 at 8:35 a.m. ET
on BusinessWire - BZX

Global Psoriasis Therapeutics Market Opportunities 2018: Merck & Co. Inc., UCB S.A, Novartis International AG, Incyte Corp

Mar. 14, 2018 at 7:46 a.m. ET
on marketresearch.biz

Report: Exploring Fundamental Drivers Behind Old Republic International, NiSource, MasTec, Lincoln National, Oceaneering International, and Incyte -- New Horizons, Emerging Trends, and Upcoming Developments

Report: Exploring Fundamental Drivers Behind Old Republic International, NiSource, MasTec, Lincoln National, Oceaneering International, and Incyte -- New Horizons, Emerging Trends, and Upcoming Developments

Mar. 8, 2018 at 8:10 a.m. ET
on GlobeNewswire

Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018

Feb. 28, 2018 at 9:00 a.m. ET
on BusinessWire - BZX

Incyte to Present at Upcoming Investor Conferences

Feb. 20, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Wired News - Asterias Biotherapeutics Expands its Global IP Portfolio with New Patents

Feb. 20, 2018 at 7:41 a.m. ET
on ACCESSWIRE

Incyte Corporation to Host Earnings Call

Feb. 15, 2018 at 6:13 a.m. ET
on ACCESSWIRE

Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Feb. 7, 2018 at 4:01 p.m. ET
on BusinessWire - BZX

Incyte to Present at Upcoming Investor Conference

Feb. 6, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Today's Research Reports on Trending Tickers: Incyte Corporation and Intrexon Corporation

Feb. 1, 2018 at 11:23 a.m. ET
on ACCESSWIRE

Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results

Jan. 31, 2018 at 4:30 p.m. ET
on BusinessWire - BZX

Incyte to Report Fourth Quarter and Year-End Financial Results

Jan. 24, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation

Jan. 23, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Stock Review for Biotech's Investors -- Gilead Sciences, ImmunoGen, Incyte, and Infinity Pharma

Jan. 23, 2018 at 6:55 a.m. ET
on PR Newswire - PRF

Today's Research Reports on Stocks to Watch: Concert Pharmaceuticals and Exact Sciences Corporation

Jan. 15, 2018 at 8:12 a.m. ET
on ACCESSWIRE

Today's Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation

Jan. 12, 2018 at 8:20 a.m. ET
on ACCESSWIRE

Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding

Jan. 12, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Worldwide Alpha Thalassemia Market Expected To Reach 8.8% CAGR by Key Vendors Revenue, Share and Forecasts To 2023

Jan. 11, 2018 at 8:59 a.m. ET
on Financeswire

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 20 Full Ratings

Ionis Pharmaceuticals’ Valuation as of March 27, 2018

Mar. 28, 2018 at 2:49 p.m. ET
on MarketRealist.com

Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades

Jan. 12, 2018 at 1:48 p.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For January 2, 2018

Jan. 2, 2018 at 9:30 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Amgen Inc.	-1.24%	$124.07B
Geron Corp.	-3.57%	$584.78M
Celgene Corp.	-0.93%	$66.82B
AVEO Pharmaceuticals Inc.	-6.36%	$280.53M
Novartis AG ADR	-0.33%	$213.44B

Competitor Data Provided By

Dow	24,191.19	-314.03	-1.28%
S&P 500	2,637.21	-25.63	-0.96%
Nasdaq	7,016.14	-60.41	-0.85%
GlobalDow	3,018.57	-17.74	-0.58%
Gold	1,335.10	6.60	0.50%
Oil	62.39	-1.15	-1.81%

Incyte Corp.

$ 68.19

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Incyte stock price target cut to $70 from $94 at Evercore ISI

Incyte's stock on track to open at 2-year low

Incyte shares fall 19% after resuming trade following a halt

Merck shares slide 1.5% premarket after news of failed drug trial

Incyte, Merck don't expect phase 3 study of melanoma treatment to meet 2nd endpoint

Incyte, Merck said an external DMC determined study of melanoma treatment missed endpoint

Incyte stock halted premarket for news pending

Incyte upgraded to outperform vs. sector perform at RBC

Stocks

Columns

Authors

Topics

^$ 68.19